Author Claim Review

 Quick Explanation Copied

 Long Explanation

Publication Record and Citation Metrics

OpenAlex data for Layla Thurston (ORCID 0000-0001-5120-9216) records 60 works with 861 total citations and an h-index of 10. Her citation trajectory is strongly COVID-era shaped: citations rose from ~12/year (2019) to a peak of ~163/year (2022), sustained at 135–137 in 2023–2024 before dipping to 93 in 2025. The acceleration was driven by two co-authored COVID-19 endocrine papers — a Lancet Diabetes & Endocrinology study of serum cortisol and COVID-19 mortality (255 citations) and a JCEM study of thyroid function before, during, and after COVID-19 (218 citations) — both published in 2020. Cortisol and COVID-19 mortality study Thyroid function in COVID-19 study

Core Research Program: Kisspeptin and Sexual Desire Neuroendocrinology

Her topic profile is dominated by kisspeptin (score 0.99), hormone biology, and endocrinology. She is first author on three influential interventional studies in this area: a JAMA Network Open randomized trial showing kisspeptin administration improves psychometric and neural measures in women with hypoactive sexual desire disorder (HSDD; 29 citations), a Journal of Clinical Investigation study of melanocortin 4 receptor agonism enhancing sexual brain processing in women with HSDD (21 citations), and a widely used clinical review of subfertility investigation in the Journal of Clinical Pathology (97 citations, first-authored). Kisspeptin RCT in female HSDD MC4R agonism in HSDD study Subfertility investigation review

As a middle author, she contributed to the group's mechanistic extensions — kisspeptin effects on penile tumescence and sexual brain processing in men with HSDD (31 citations), kisspeptin modulation of food-image brain responses and appetite (27 citations), and kisspeptin modulation of GABA levels in the human brain via proton MR spectroscopy (26 citations). Kisspeptin in male HSDD study Kisspeptin-GABA MRS study

Strengths and Critical Limitations

Strengths: publication venues are high quality (JAMA Network Open, JCI, Lancet D&E, JCEM); she combines interventional human physiology (hormone challenge + fMRI + psychometrics) — a rigorous translational design — with clinical review output. Almost all recent works are open access, and productivity accelerated sharply from 2022 (16 works) onward, consistent with an active research pipeline.
Limitations and blindspots: first, the h-index of 10 against 861 citations indicates most citation mass comes from a handful of co-authored COVID-era papers rather than her first-author kisspeptin work, which remains modestly cited (21–31 citations) relative to its venue prestige — translational impact is not yet demonstrated at scale. Second, authorship patterns show heavy dependence on one group (Dhillo/Comninos/Mills at Imperial College, plus Invicro co-authors); no primary institution is even listed in OpenAlex, and her early career includes rheumatology cohort work at Leeds (2014 anti-TNF adherence study), suggesting a shifting early research identity. Third, the COVID studies are observational and suffer the usual confounding (illness severity, admission criteria); the cortisol–mortality association in particular is vulnerable to reverse causation since acute critical illness itself raises cortisol. Fourth, HSDD studies have small samples typical of challenge-fMRI designs, limiting generalizability and precluding firm effect-size claims. Finally, one of her top works shows a metadata error in OpenAlex (journal listed as "Lara D. Veeken"), a minor data-quality flag for bibliometric analysis.

Verdict

Thurston is a solid, productive clinical neuroendocrinology researcher with genuine first-author trial leadership in a distinctive niche (kisspeptin/MC4R modulation of sexual desire), embedded in a strong translational group. Her metrics reflect a rising specialist whose citation capital currently rests more on opportunistic COVID-era co-authorship than on her core program; establishing independent leadership and demonstrating real-world clinical impact of kisspeptin-based approaches will determine whether she moves beyond this level.

 BGPT Author Review

Scientific Quality

Thurston shows genuine trial leadership (first-author randomized hormone-challenge fMRI studies in HSDD in JAMA Network Open and JCI) within a respected translational group, plus a clinically useful subfertility review. However, her h-index of 10 over 60 works is modest; her citation mass derives largely from middle-author COVID observational papers, not her core first-author program. The cortisol–COVID mortality study is confounded by illness severity. Strong specialist, not yet demonstrated independent scientific leader.

Communication Quality

Her subfertility review is a clear, practically structured clinical educational piece with strong uptake, and her trial reports appear in accessible open-access venues. Communication strength lies in clinical clarity; there is less evidence of broad popularization or methodological writing.

Author Novelty

Using kisspeptin and melanocortin agonism to probe and treat sexual desire neurocircuitry in humans is a genuinely distinctive, inventive niche pioneered largely by the Imperial College group; Thurston holds first-author roles on several of these first-in-class human studies. Not globally groundbreaking (the group's framework predates her lead roles), but the specific application is novel.

Scientific Rigor

Her first-author work uses controlled human intervention designs with objective endpoints (fMRI, psychometrics, tumescence), reflecting solid rigor. Deductions: small samples typical of challenge studies, the observational cortisol–mortality study's confounding vulnerability, and apparent limited independent analytic leadership. No evidence of p-hacking or misconduct; rigor is good but bounded by design scale.